Highlights Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
196.52 ^USD	+0.52%		-2.32%	+11.67%

02-13	Biogen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:30 AM
02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…

Highlights

02-09	Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says	MT
02-09	All or Nothing Week
02-09	Bioarctic AB for Subcutaneous Formulation of Leqembi Designated for Priority Review in China	CI
02-06	Biogen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-06	Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020.	CI
02-06	Biogen Q4 Non-GAAP Earnings, Revenue Fall; 2026 Outlook Set -- Shares Up Pre-Bell	MT
02-06	(BIIB) Biogen Expects 2026 Adjusted EPS Range $15.25 to $16.25, vs. FactSet Est of $14.93	MT
02-06	Earnings Flash (BIIB) Biogen Posts Q4 Total Revenue $2.28B, vs. FactSet Est of $2.20B	MT
02-06	Earnings Flash (BIIB) Biogen Posts Q4 Adjusted EPS $1.99, vs. FactSet Est of $1.63	MT
02-06	Biogen sees 2026 adj EPS $15.25 - $16.25 versus IBES estimate $14.92	RE
02-06	Eisai Co Ltd - revenue of Leqembi (preliminary basis)	RE
02-06	Biogen forecasts upbeat annual profit, eyes 2028 launch of key drugs	RE
02-04	Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy	CI
01-28	Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease with No Targeted Treatment Options	CI
01-26	Sector Update: Health Care Stocks Advance Late Afternoon	MT
01-26	Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®?	CI
01-26	Planting Hedges Early
01-26	Biogen Says FDA Accepts to Review Marketing Application for Weekly Alzheimer's Injection	MT
01-26	Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review	CI
01-25	Eisai & Biogen say U.S. FDA accepts Leqembi supplemental biologics license application as subcutaneous starting dose for treatment of early Alzheimer's under Priority Review	RE
01-14	Biogen Expects Q4 Expense of $222 Million	MT
01-14	Biogen - Charge to impact Q4 net income by $1.26 per share - SEC filing	RE
01-12	Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026	CI
01-12	Biogen Wins EU Approval for High-Dose Spinraza Regimen for Spinal Muscular Atrophy	MT
01-12	Biogen says co received European Commission approval for high dose regimen of Spinraza	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Highlights

Filters